Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Work In Process (2016 - 2026)

Avanos Medical's Work In Process history spans 12 years, with the latest figure at $25.2 million for Q4 2025.

  • On a quarterly basis, Work In Process rose 19.43% to $25.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.2 million, a 19.43% increase, with the full-year FY2025 number at $25.2 million, up 19.43% from a year prior.
  • Work In Process hit $25.2 million in Q4 2025 for Avanos Medical, down from $29.3 million in the prior quarter.
  • Over the last five years, Work In Process for AVNS hit a ceiling of $34.8 million in Q3 2021 and a floor of $19.8 million in Q4 2023.
  • Historically, Work In Process has averaged $27.9 million across 5 years, with a median of $27.2 million in 2024.
  • Biggest five-year swings in Work In Process: plummeted 31.7% in 2023 and later rose 26.29% in 2025.
  • Tracing AVNS's Work In Process over 5 years: stood at $33.2 million in 2021, then fell by 28.31% to $23.8 million in 2022, then dropped by 16.81% to $19.8 million in 2023, then grew by 6.57% to $21.1 million in 2024, then grew by 19.43% to $25.2 million in 2025.
  • Business Quant data shows Work In Process for AVNS at $25.2 million in Q4 2025, $29.3 million in Q3 2025, and $28.5 million in Q2 2025.